Prestige Consumer Healthcare (NYSE:PBH) Stock Price Expected to Rise, Oppenheimer Analyst Says

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its target price lifted by Oppenheimer from $87.00 to $93.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's price objective suggests a potential upside of 10.70% from the company's previous close.

A number of other analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Finally, Canaccord Genuity Group increased their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and an average price target of $92.60.

Read Our Latest Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Trading Down 0.2 %

Shares of NYSE:PBH traded down $0.20 during trading hours on Thursday, hitting $84.01. 51,000 shares of the company's stock traded hands, compared to its average volume of 310,483. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $88.36. The firm has a market capitalization of $4.15 billion, a P/E ratio of 19.67, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50. The business has a fifty day moving average price of $79.27 and a 200-day moving average price of $75.80. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC acquired a new stake in Prestige Consumer Healthcare during the fourth quarter worth about $40,000. nVerses Capital LLC raised its position in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company's stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Finally, Huntington National Bank lifted its holdings in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Articles

• Five stocks we like better than Prestige Consumer Healthcare
• 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
• Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
• Following Congress Stock Trades
• Buffett Buys More Occidental Petroleum—Sticking to His Playbook
• What is the MACD Indicator and How to Use it in Your Trading
• CVS Health: Earnings Beat Ignites Stock Rally

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?

Before you consider Prestige Consumer Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.

While Prestige Consumer Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here